This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients’ Lipid Profiles

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2006 by China Medical University Hospital.
Recruitment status was:  Recruiting
Information provided by:
China Medical University Hospital Identifier:
First received: April 20, 2006
Last updated: November 6, 2006
Last verified: March 2006
The purpose of this study is to determine whether the Lipid-lowing Tea is effective and safe in the treatment of Hyperlipidemia Patients

Condition Intervention Phase
Hyperlipidemia Drug: Lipid-lowing Tea Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double

Resource links provided by NLM:

Further study details as provided by China Medical University Hospital:


Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patient aged 20-65 years;either sex
  • Patient diagnosed with hyperlipidemia(fasting levels of TC>=200mg/dL),or TG>=200mg/dL but <400mg/dL,or LDL-C>=130mg/dL)
  • Patient who has signed the informed consent form

Exclusion Criteria:

  • Patient with pregnancy (or child bearing potential),or in lactation
  • Patient with any lipid regulating agents within 4 weeks prior to study period
  • Patient currently taking concomitant medications, such as oral contraceptives, or any medical treatment capable of interfering with lipid metabolism(eg thiazides, β-blockers, cyclosporins, itraconazole erythromycin,and danazol)
  • Patient with medical history of hypothyroidism, pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, primary biliary cirrhosis.
  • Patient with liver dysfunction (SGOT or SGPT>2x ULN)
  • Patient with renal insufficiency (serum creatinine>1.3mg/dL)
  • Patient with myocardial infarction,cerebrovascular disease,or major operations within 6 months prior to the study period.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00316641

Contact: Chia-I Tsai, V.S 886-4-22052121 ext 5065

China Medical University Hospital Recruiting
Taichung, Taiwan, 404
Contact: Chia-I Tsai, MD    886-4-22052121 ext 5065   
Principal Investigator: Chia-I Tsai, MD         
Sponsors and Collaborators
China Medical University Hospital
Principal Investigator: Chia-I Tsai, V.S China Medical University Hospital,Taichung,Taiwan
  More Information Identifier: NCT00316641     History of Changes
Other Study ID Numbers: DMR93-IRB-71
Study First Received: April 20, 2006
Last Updated: November 6, 2006

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases processed this record on September 21, 2017